Kaiku Health will present two scientific abstracts at the ESMO Virtual Congress 2020. The research has been conducted in collaboration with Oulu University Hospital and it investigates combining machine learning, patient-reported symptom data and lab measurements to analyse treatment response and predict the onset of immune-related adverse events in immune checkpoint inhibitor therapies.
The two research abstracts presented at ESMO 2020 include:
1.“Predicting the onset of immune-related adverse events (irAEs) in immune checkpoint inhibitor (ICI) therapies using a machine learning (ML) model trained with electronic patient-reported outcomes (ePROs) and lab measurements”
First author: Sanna Iivanainen (Oulu University Hospital)
Poster #: 1841P
2.“A combination model of electronic patient-reported outcomes (ePROs) and lab measurements in prediction of immune related adverse events (irAEs) and treatment response of immune checkpoint inhibitor (ICI) therapies”
First author: Sanna Iivanainen (Oulu University Hospital)
Poster #: 1876P
The posters will be presented at the ESMO Virtual Congress 2020 from September 17th to September 21st on the Congress platform. The congress is one of the leading global events in the field of oncology, organised by the European Society for Medical Oncology. Annually significant and some of the most promising scientific research in the field of oncology is presented at the congress.
About Kaiku Health
Kaiku Health is a digital health intervention platform classified as a Medical Device in cancer care. Its algorithms screen symptoms, notify the care team and provide personalised support for patients. Kaiku Health has modules for over 25 cancer types across different cancer care pathways and is currently in use in leading European cancer clinics and hospitals. Kaiku Health is a part of Elekta.
